788 related articles for article (PubMed ID: 15516696)
41. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients.
Chan JC; Ko GT; Leung DH; Cheung RC; Cheung MY; So WY; Swaminathan R; Nicholls MG; Critchley JA; Cockram CS
Kidney Int; 2000 Feb; 57(2):590-600. PubMed ID: 10652036
[TBL] [Abstract][Full Text] [Related]
42. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy.
Alter ML; Ott IM; von Websky K; Tsuprykov O; Sharkovska Y; Krause-Relle K; Raila J; Henze A; Klein T; Hocher B
Kidney Blood Press Res; 2012; 36(1):119-30. PubMed ID: 23171828
[TBL] [Abstract][Full Text] [Related]
43. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.
Fallahzadeh MK; Dormanesh B; Sagheb MM; Roozbeh J; Vessal G; Pakfetrat M; Daneshbod Y; Kamali-Sarvestani E; Lankarani KB
Am J Kidney Dis; 2012 Dec; 60(6):896-903. PubMed ID: 22770926
[TBL] [Abstract][Full Text] [Related]
44. Nitrendipine and enalapril improve albuminuria and glomerular filtration rate in non-insulin dependent diabetes.
Mosconi L; Ruggenenti P; Perna A; Mecca G; Remuzzi G
Kidney Int Suppl; 1996 Jun; 55():S91-3. PubMed ID: 8743521
[TBL] [Abstract][Full Text] [Related]
45. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period.
White WB; Lacourciere Y; Davidai G
Am J Hypertens; 2004 Apr; 17(4):347-53. PubMed ID: 15062889
[TBL] [Abstract][Full Text] [Related]
46. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension.
Estacio RO; Jeffers BW; Hiatt WR; Biggerstaff SL; Gifford N; Schrier RW
N Engl J Med; 1998 Mar; 338(10):645-52. PubMed ID: 9486993
[TBL] [Abstract][Full Text] [Related]
47. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial.
Rossing K; Jacobsen P; Pietraszek L; Parving HH
Diabetes Care; 2003 Aug; 26(8):2268-74. PubMed ID: 12882847
[TBL] [Abstract][Full Text] [Related]
48. Telmisartan, ramipril, or both in patients at high risk for vascular events.
; Yusuf S; Teo KK; Pogue J; Dyal L; Copland I; Schumacher H; Dagenais G; Sleight P; Anderson C
N Engl J Med; 2008 Apr; 358(15):1547-59. PubMed ID: 18378520
[TBL] [Abstract][Full Text] [Related]
49. Telmisartan vs. enalapril in type 2 diabetes.
Loewenstein JE
N Engl J Med; 2005 Feb; 352(8):835-6; author reply 835-6. PubMed ID: 15736291
[No Abstract] [Full Text] [Related]
50. Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy.
Fujisawa T; Ikegami H; Ono M; Nishino M; Noso S; Kawabata Y; Ogihara T
Am J Hypertens; 2005 Jan; 18(1):13-7. PubMed ID: 15691611
[TBL] [Abstract][Full Text] [Related]
51. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
Mann JF; Schmieder RE; McQueen M; Dyal L; Schumacher H; Pogue J; Wang X; Maggioni A; Budaj A; Chaithiraphan S; Dickstein K; Keltai M; Metsärinne K; Oto A; Parkhomenko A; Piegas LS; Svendsen TL; Teo KK; Yusuf S;
Lancet; 2008 Aug; 372(9638):547-53. PubMed ID: 18707986
[TBL] [Abstract][Full Text] [Related]
52. Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. The replacement of angiotensin converting enzyme inhibition (REPLACE) investigators.
Dunselman PH;
Int J Cardiol; 2001 Feb; 77(2-3):131-8; discussion 139-40. PubMed ID: 11182175
[TBL] [Abstract][Full Text] [Related]
53. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study.
Nielsen SE; Persson F; Frandsen E; Sugaya T; Hess G; Zdunek D; Shjoedt KJ; Parving HH; Rossing P
Diabet Med; 2012 Aug; 29(8):e184-90. PubMed ID: 22268920
[TBL] [Abstract][Full Text] [Related]
54. Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus.
Rosei EA; Rizzoni D; Muiesan ML; Sleiman I; Salvetti M; Monteduro C; Porteri E;
J Hypertens; 2005 Feb; 23(2):435-44. PubMed ID: 15662233
[TBL] [Abstract][Full Text] [Related]
55. Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study.
Makino H; Haneda M; Babazono T; Moriya T; Ito S; Iwamoto Y; Kawamori R; Takeuchi M; Katayama S;
Hypertens Res; 2008 Apr; 31(4):657-64. PubMed ID: 18633177
[TBL] [Abstract][Full Text] [Related]
56. ACE-inhibition and renoprotection in early diabetic nephropathy. Response to enalapril acutely and in long-term combination with conventional antihypertensive treatment.
Pedersen MM; Christensen CK; Hansen KW; Christiansen JS; Mogensen CE
Clin Invest Med; 1991 Dec; 14(6):642-51. PubMed ID: 1665407
[TBL] [Abstract][Full Text] [Related]
57. Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria.
Jerums G; Allen TJ; Campbell DJ; Cooper ME; Gilbert RE; Hammond JJ; O'Brien RC; Raffaele J; Tsalamandris C;
Diabet Med; 2004 Nov; 21(11):1192-9. PubMed ID: 15498085
[TBL] [Abstract][Full Text] [Related]
58. [Urinary albumin excretion in non-insulin-dependent diabetic patients. Effects of an angiotensin-converting enzyme inhibitor].
Durruty P; Tapia JC; Ugarte C; Pérez E; Krause P; Soto N; García de los Ríos M
Rev Med Chil; 1996 Sep; 124(9):1036-44. PubMed ID: 9197016
[TBL] [Abstract][Full Text] [Related]
59. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.
; Yusuf S; Teo K; Anderson C; Pogue J; Dyal L; Copland I; Schumacher H; Dagenais G; Sleight P
Lancet; 2008 Sep; 372(9644):1174-83. PubMed ID: 18757085
[TBL] [Abstract][Full Text] [Related]
60. Losartan ameliorates progression of glomerular structural changes in diabetic KKAy mice.
Sasaki M; Uehara S; Ohta H; Taguchi K; Kemi M; Nishikibe M; Matsumoto H
Life Sci; 2004 Jul; 75(7):869-80. PubMed ID: 15183078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
